Vanda Pharmaceuticals Inc (STU:VM4) Stock News, Headlines & Updates
Vanda Pharmaceuticals Inc Stock News from GuruFocus
- 1
Jun 17, 2025
Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)
GuruFocus News • 11:00pm
Jun 10, 2025
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
PRNewswire • 8:00am
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News
GuruFocus News • 7:40am
Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Antisense Therapy | VNDA Stock News
GuruFocus News • 7:18am
May 27, 2025
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
PRNewswire • 9:00am
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News
GuruFocus News • 8:20am
May 22, 2025
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA)
GuruFocus News • 11:00pm
May 20, 2025
Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)
GuruFocus News • 1:02am
May 16, 2025
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
PRNewswire • 5:00pm
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News
GuruFocus News • 4:45pm
May 14, 2025
Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock News
GuruFocus News • 9:42am
Vanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock News
GuruFocus News • 7:12am
May 08, 2025
Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses
GuruFocus News • 1:28am
Q1 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
GuruFocus News • 11:13pm
May 07, 2025
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
PRNewswire • 4:00pm
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million
GuruFocus News • 3:51pm
Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News
GuruFocus News • 3:16pm
HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA) | VNDA Stock News
GuruFocus News • 8:30am
May 05, 2025
Vanda Announces Bysantiâ„¢ NDA Filing; FDA Decision Expected in Early 2026
PRNewswire • 8:00am
Vanda Announces Bysantiâ„¢ NDA Filing; FDA Decision Expected in Early 2026 | VNDA Stock News
GuruFocus News • 7:21am
FDA Begins Review Process on Vanda Pharmaceuticals' (VNDA) Drug Application | VNDA Stock News
GuruFocus News • 7:18am
May 02, 2025
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 | VNDA Stock News
GuruFocus News • 8:00am
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
PRNewswire • 8:00am
Apr 23, 2025
Vanda Pharmaceuticals (VNDA) Criticizes FDA Over Tradipitant Hearing Delay | VNDA Stock News
GuruFocus News • 3:38pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news